Taysha Gene Therapies FY23 EPS $(0.96) Vs $(3.78) YoY; As Of December 31, 2023, Taysha Had $143.9M In Cash And Cash Equivalents
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies reported a significant improvement in its FY23 financial results, with EPS improving to $(0.96) from $(3.78) YoY. Revenue increased to $15.5 million, primarily from its Option Agreement with Audentes Therapeutics (Astellas Gene Therapies), focusing on Rett syndrome research. R&D expenses decreased to $56.8 million, and G&A expenses to $30.0 million, contributing to a reduced net loss of $111.6 million. The company ended the year with $143.9 million in cash, expecting to support operations into 2026.
March 19, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies reported improved FY23 financials with higher revenue, reduced expenses, and a strong cash position, indicating a positive outlook for the company.
The significant improvement in EPS, increase in revenue, and reduction in net loss, combined with a strong cash position, suggest a positive short-term impact on TSHA's stock price. The financial stability and expected operational support into 2026 may increase investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100